Description

LEESGGGLVQPGGSMK acetate, a proteolysis peptide, is a component of Infliximab. LEESGGGLVQPGGSMK acetate can be used for quantitative analysis of Infliximab. Infliximab is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α[1].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)–COVID-19-immunoregulation–C66H112N18O26S—-[1]Dorothée LEBERT, et al. A method for quantifying therapeutic antibodies. EP3371592A1.—-1605.76–99.01–O=C(N[C@@H](CCC(O)=O)C(N[C@@H](CCC(O)=O)C(N[C@@H](CO)C(NCC(NCC(NCC(N[C@@H](CC(C)C)C(N[C@@H](C(C)C)C(N[C@@H](CCC(N)=O)C(N1[C@@H](CCC1)C(NCC(NCC(N[C@@H](CO)C(N[C@@H](CCSC)C(N[C@@H](CCCCN)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CC(C)C)N.CC(O)=O–Inflammation/Immunology–H2O : 100 mg/mL (ultrasonic)–TNF Receptor—-Apoptosis–Peptides